Patents by Inventor Sara Colombetti

Sara Colombetti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY OF PD-1-TARGETED IL-2 VARIANT IMMUNOCONJUGATES AND FAP/4-1BB BINDING MOLECULES
    Publication number: 20240092856
    Abstract: The present invention relates to the combination therapy of specific PD-1-targeted IL-2 variant immunoconjugates with specific antibodies which bind human FAP and 4-1BB and optionally with an anti-CEA/anti-CD3 bispecific antibody.
    Type: Application
    Filed: March 8, 2022
    Publication date: March 21, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina BACAC, Christina CLAUS, Laura CODARRI DEAK, Sara COLOMBETTI, Christian KLEIN, Valeria G. NICOLINI, Mario PERRO, Johannes SAM, Christine TRUMPFHELLER, Pablo UMAÑA
  • METHODS OF TREATING CEA-POSITIVE CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND ANTI-CEA/ANTI-CD3 BISPECIFIC ANTIBODIES
    Publication number: 20200376119
    Abstract: The invention provides compositions and methods for treating CEA-positive cancers. The method comprising administering a PD-1 axis binding antagonist and a bispecific antibody that targets CEA and CD3.
    Type: Application
    Filed: February 11, 2020
    Publication date: December 3, 2020
    Inventors: Marina BACAC, Sara COLOMBETTI, Christian KLEIN, Johannes SAM, Jose SARO, Pablo UMANA
  • TYPE II ANTI-CD20 ANTIBODY AND ANTI-CD20/CD3 BISPECIFIC ANTIBODY FOR TREATMENT OF CANCER
    Publication number: 20200172627
    Abstract: The present invention relates to methods of treating a disease, and methods for reduction of cytokine release associated with the administration of a T-cell activating therapeutic agent. The present invention further relates to combination treatment methods of treating a disease and antibodies for the use in such methods.
    Type: Application
    Filed: November 22, 2019
    Publication date: June 4, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina BACAC, Sara COLOMBETTI, Christian KLEIN, Johannes SAM, Pablo UMAÑA
  • Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies
    Patent number: 10596257
    Abstract: The invention provides compositions and methods for treating CEA-positive cancers. The method comprising administering a PD-1 axis binding antagonist and a bispecific antibody that targets CEA and CD3.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: March 24, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marina Bacac, Sara Colombetti, Christian Klein, Johannes Sam, Jose Saro, Pablo Umana
  • METHODS OF TREATING CEA-POSITIVE CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND ANTI-CEA/ANTI-CD3 BISPECIFIC ANTIBODIES
    Publication number: 20180000931
    Abstract: The invention provides compositions and methods for treating CEA-positive cancers. The method comprising administering a PD-1 axis binding antagonist and a bispecific antibody that targets CEA and CD3.
    Type: Application
    Filed: January 5, 2017
    Publication date: January 4, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina Bacac, Sara Colombetti, Christian Klein, Johannes Sam, Jose Saro, Pablo Umana